- DIAGNOS (ADK) has deployed its Age-Related Macular Degeneration detection application into the optometry clinics of IRIS The Visual Group
- Age-Related Macular Degeneration (AMD) is a leading cause of visual deterioration and legal blindness in people over 60 years of age
- DIAGNOS is currently putting the finishing touches on several Artificial Intelligence Deep Learning algorithms focused on disease detection
- DIAGNOS is a Canadian corporation focusing on early detection of critical health problems using its FLAIRE Artificial Intelligence (AI) platform
- DIAGNOS Inc. (ADK) remains unchanged, trading at C$0.165 per share as of 2:00 pm ET
DIAGNOS (ADK) has deployed its Age-Related Macular Degeneration detection application into the optometry clinics of IRIS The Visual Group.
Yves-Stéphane Couture, Vice-President of DIAGNOS commented on the news.
“With over 1,250 patients having received this new test already, we can see that the demand is great for this application in clinical optometry and optical retail. We are thrilled by the addition of the AMD detection application into our portfolio. It further expands the value our company offers to eyecare providers, an important segment of our market expansion strategy.”
Age-Related Macular Degeneration (AMD) is a leading cause of visual deterioration and legal blindness in people over 60 years of age.
The loss of central vision and high-resolution visual acuity from untreated AMD can lead to irreversible reading loss, depression, reduced facial recognition ability, and disqualification from driving. Regular screening for eye diseases is essential to enable early detection and prevention.
DIAGNOS is currently putting the finishing touches on several Artificial Intelligence Deep Learning algorithms focused on disease detection. It aims to improve clinical operations and patient outcomes. The launch of the AMD detection application is the first in a series of important launches planned soon, that will ensure the success and sustainability of the organization.
DIAGNOS is a Canadian corporation focusing on early detection of critical health problems using its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis).
CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.
DIAGNOS Inc. (ADK) remains unchanged, trading at C$0.165 per share as of 2:00 pm ET.
